Angiomax® or Unfractionated Heparin for Patients Undergoing Percutaneous Coronary Intervention
Status:
Terminated
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to assess the safety and efficacy of Angiomax® (bivalirudin)
versus unfractionated heparin (UFH) in patients presenting with stable angina or silent
ischemia (positive stress test without chest pain) that undergo percutaneous coronary
intervention (PCI).
The primary endpoint of the study will be major and minor bleeding events, defined by the
REPLACE-2 trial definition, during the index hospitalization and up to 30 days post
discharge.